Major Depressive Disorder Clinical Trial
Official title:
A Randomized, Comparator-Controlled, Two-Arm, Parallel Group Study to Determine the Safety and Efficacy of eCBT Mood®, a Handheld, Computerized, Electronic Cognitive Behavioral Therapy Application, in Patients With Major Depressive Disorder
The primary objective of this study is to evaluate the safety and efficacy of an electronic cognitive behavioral therapy application (eCBT Mood) compared to a control group consisting of a mood monitoring handheld computer application in the treatment of patients with mild to moderate major depressive disorder.
This is a prospective, randomized, comparator-controlled, two-arm, parallel group study to
examine the safety and efficacy of eCBT Mood, a handheld, computerized, electronic cognitive
behavioral therapy (CBT) application, in patients with major depressive disorder (MDD). The
study will involve 100 patients with mild to moderate MDD randomly assigned to daily use of
either a CBT application focused on depression ('eCBT Mood'; MindApps, llc) or a
comparator-controlled group using a mood monitoring application ('Mood Tracker'; GP
International). This study design and duration of the study is consistent with other studies
employing comparator-controlled designs in the study of CBT interventions, including
computerized CBT interventions, among patients with MDD (e.g., Andrews et al., 2010;
McKendree-Smith et al., 2003).
After being screened to ensure that the patients meet the required diagnostic, depression
severity, and other inclusion criteria, patients will be randomly assigned (1:1) to use
either eCBT Mood, a computer application running on the Apple® iPhoneâ„¢ or iPod Touch®
handheld computer platforms. The application includes: (1) a psychoeducation module on the
relationships among thoughts, feelings, and behaviors, (2) a 6-item daily depression
assessment with the option to e-mail the summary score and suicidal ideation assessment
response to a 3rd party, (3) a negative automatic thought identification module, (4) a
feelings and thoughts log, (5) a module enabling the user to challenge their negative
automatic thoughts, (6) an assessment and challenge module regarding core beliefs which
underlie many automatic thoughts, (7) optional compliance reminders to use the application
or take medicines, and (8) links to behavioral science-based online content regarding MDD
from PsychCentral (see www.psychcentral.com). In contrast, the comparator control condition
will use Mood Tracker, which is also a a computer application running on the Apple iPhone or
iPod Touch handheld computer platforms. This application enables users to rate their mood
using expressive faces on a daily basis, log about their daily feelings, and also has an
option enabling an e-mail to be sent to a 3rd party regarding their daily mood ratings.
Throughout the 8-week study period, patients will complete both in-person and
telephone-based assessments of their depression severity, mood, frequency of negative
automatic thoughts, and safety assessments.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |